Pharma major Cipla On July 8 said it has launched its generic version of antiviral drug remdesivir. Cipla said it has been launched at a price which is among the lowest globally & is looking to supply over 80,000 vials within the first month. The company, however, did not disclose the price of the medicine. Cipla had earlier said the drug will be priced at less than Rs 5,000 per 100 mg vial in line with its overall philosophy of driving access & affordability. Cipremi has been approved by the Drug Controller General of India (DCGI) for restricted emergency use in the country. This is part of the accelerated approval process considering the urgent & unmet medical need. Remdesivir is the only United States Food and Drug Administration (USFDA)-approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection. India is now the third worst hit nation by coronavirus with over seven lakh cases, behind Brazil and the United States.
Google Trends
Live Bot